Could psychedelics be the brain’s next breakthrough medicine? New science reveals how they rewire neurons and calm ...

“These findings may provide novel insights into the weight fluctuations after GLP-1 RA treatment in the real-world setting, thereby advancing the development of individualized strategies with ...

Work at Ensem Therapeutics Inc. has led to the discovery of anilino-pyrazole derivatives acting as cannabinoid CB2 receptor agonists. As such, they are reported to be useful for the treatment of ...

THURSDAY, July 17, 2025 (HealthDay News) -- For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased risk for gastroesophageal reflux ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists are associated with an increased risk for gastroesophageal reflux disease and its complications compared with ...

TUESDAY, July 15, 2025 (HealthDay News) -- For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), ...

GLP-1 receptor agonists and amylin receptor agonists have shown clinically relevant weight loss and glucose-lowering effects in people with overweight, obesity, and type 2 diabetes. Amycretin is a ...

G protein-coupled receptors (GPCRs) make up the largest receptor family in humans, which also constitute principal molecular targets for about 36% of approved drugs. Recent studies show that GPCRs can ...